Article Information
History
- June 2, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Ricky Y. T. Chiu1,2,
- Noah Kojima3,*,
- Garrett Lee Mosley2,
- Kwok Kin Cheng2,
- David Y. Pereira1,
- Matthew Brobeck1,
- Tsun Leung Chan4,
- Jonpaul Sze-Tsing Zee4,
- Harsha Kittur2,
- Tenny Cheuk-Yiu Chung2,
- Eric Tsang1,
- Kajal Maran1,
- Raymond Wai-Hung Yung4,
- Alex Chin-Pang Leung4,
- Ryan Ho-Ping Siu2,
- Jessica Pui-Ling Ng2,
- Tsz Hei Choi2,
- Mei Wai Fung2,
- Wai Sing Chan4,
- Ho Yin Lam4,
- Koon Hung Lee5,
- Sean Parkin6,
- Felix C. Chao1,
- Stephen Ka-Nung Ho2,
- Daniel R. Marshak1,2,
- Edmond Shiu-Kwan Ma4 and
- Jeffrey D. Klausner7
- 1Phase Scientific International Ltd., Garden Grove, CA, USA
- 2Phase Scientific International Ltd., Kwun Tong, Hong Kong
- 3Department of Medicine, University of California Los Angeles, Los Angeles, 90095
- 4Department of Pathology, Hong Kong Sanatorium and Hospital
- 5Department of Hospital Administration, Hong Kong Sanatorium and Hospital
- 6CityHealth Urgent Care, Alameda, CA, USA
- 7Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California
- ↵*Correspondence:
N. Kojima, Department of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095. Email: nkojima{at}ucla.edu
Posted June 02, 2021.
Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test in symptomatic populations and asymptomatic community testing
